Keyvibe-010 fails, but not for the reason you might have expected.

Lilly’s Mablink acquisition challenges Genmab’s move for ProfoundBio.

Tamarack data reveal vobra-duo’s toxicity, and wipe out the past six months’ share price gains.

But the group’s attempt to join Janux at the high altar of masking technology falls flat.

A tumour-agnostic label for Enhertu leads April’s US oncology approvals.